MAPK1 and non-small cell lung carcinoma: Further interruption of both STAT3-survivin and ERK-BIM pathways was critical for induction of apoptosis in NSCLC harbouring EML4-ALK—this was accomplished using ALK and MEK inhibitors in EML4-ALK-positive NSCLC patients for whom ALK inhibitors alone are ineffective [151].